Equecabtagene Autoleucel Injection (Eque-cel) is being evaluated in a Phase III trial for lenalidomide-refractory relapsed/refractory multiple myeloma (RRMM). The market for multiple myeloma therapies is significant, with increasing demand for innovative treatments due to the limitations of current therapies. Eque-cel, as a CAR-T therapy targeting BCMA, positions itself in a competitive landscape alongside established therapies such as daratumumab and pomalidomide. The success of this trial could enhance Nanjing IASO Biotechnology Co., Ltd.'s market presence and potentially lead to partnerships or acquisitions, given the growing interest in CAR-T therapies. Diligence should focus on the trial's recruitment progress, safety profile, and competitive responses from other companies developing BCMA-targeted therapies.